Immunome (IMNM) Cash from Operations (2019 - 2026)

Immunome has reported Cash from Operations for 8 years, with the latest figure at 58638000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 10.52% year-over-year to 58638000.0; the trailing twelve-month figure through Mar 2026 stood at 196502000.0 (down 28.7% YoY), and the FY2025 full-year result was 190919000.0, down 72.32% from the prior year.
• Cash from Operations for Q1 2026 stood at 58638000.0, down from 47953000.0 in the prior quarter.
• The five-year high for Cash from Operations was 24173000.0 in Q1 2023, with the low at 58638000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 23329941.18 across 5 years, with a median of 17459000.0 in 2023.
• Annual changes were most pronounced in 2023 — Cash from Operations surged 479.12% — and 2025, when it sank 374.98%.
• Immunome's Cash from Operations stood at 6683000.0 in 2022, then plunged by 161.24% to 17459000.0 in 2023, then plunged by 140.91% to 42060000.0 in 2024, then dropped by 14.01% to 47953000.0 in 2025, then decreased by 22.28% to 58638000.0 in 2026.
• The last three Cash from Operations figures came in at 58638000.0 (Q1 2026), 47953000.0 (Q4 2025), and 40510000.0 (Q3 2025), per Business Quant data.